Actively Recruiting
Safety and Tolerability Study of ONO-7429 in Adults with Unresectable Advanced or Recurrent Solid Tumors
Led by Ono Pharmaceutical Co., Ltd. · Updated on 2026-08-26
80
Participants Needed
10
Research Sites
86 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of ONO-7429 in adults with unresectable advanced or recurrent solid tumors who have not responded to or cannot tolerate standard treatments. This phase 1, open-label study is sponsored by Ono Pharmaceutical Co., Ltd. and focuses on understanding how participants tolerate this investigational drug and monitoring any side effects. Participants receive ONO-7429 at specified doses on certain days, with the study designed as a single-group dose escalation to assess safety. The treatment period includes close monitoring during the dose-limiting toxicity evaluation phase, approximately 21 days, and further follow-up to assess adverse events over about six months. During the study, participants undergo various assessments including biomarker testing from tumor samples, safety evaluations, and pharmacokinetic measurements such as plasma concentration and elimination half-life. Researchers also evaluate tumor response and disease progression through imaging and clinical examinations. The study lasts up to the completion date in March 2030, with primary outcomes focused on tolerability and safety of ONO-7429.
CONDITIONS
Brief Title
A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors
Research Team
N
North America Clinical Trial Support Desk
I
International Clinical Trial Support Desk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here